Sitemap
Pages
- #6248 (no title)
- #6562 (no title)
- About Us
- Care Model
- CKM Assessment Forms
- Contact
- Continuous Quality Improvement
- Determining Cardiometabolic Program Goals and Aims
- Engaging Patients in Diabetes Self-Management
- Home
- News
- Privacy Policy
- Publications
- Search
- Terms of Use
- Antiplatelets & Anticoagulants
- GDMT Pathways & Decision Tools
- GLP-1 RA
- Insulin and Additional Oral Medication Resources
- PCSK9i
- RAASi
- SGLT2i
- Statins
- Building Teams
- Implementing Clinical Pharmacist Services
- Implementing Supplemental Services
- CMCA Metrics and Benchmark Reporting
- Prepare Documents for IRB Submission
- Diabetes Self-Management Education and Support
- Insulin and Insulin Secretagogues – Considerations When Initiating a New Glucose-Lowering Medication
- Other Medications Commonly Used in Treating Cardiometabolic Patients
- Protocol for Titration of Insulin and Insulin Secretagogues When Initiating a GLP-1 RA
- Protocol for Titration of Insulin and Insulin Secretagogues When Initiating a SGLT2i
- Manufacturer Contact List
- Program Operation Best Practices for Medical Office Support
- Quick-Phrase and Provider Visit Documentation Examples
- SBAR Template for Triaging Patients with Diabetes
- SBAR Template for Triaging Patients with Heart Failure
- Onboarding Tools
- Operational Resources
- Registry Management
- Practical Considerations for Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA)
- Protocol for Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA)
- Practical Considerations for Use of HMG-CoA Reductase Inhibitors (Statins)
- Protocol for Use of HMG-CoA Reductase Inhibitors (Statins)
- Practical Considerations for Use of Oral Antithrombotic Agents (Antiplatelets and Anticoagulants)
- Protocol for Use of Oral Antithrombotic Agents (Antiplatelets and Anticoagulants)
- Practical Considerations for Use of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors (PCSK9i) in Cardiometabolic Disease
- Protocol for Use of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors (PCSK9i)
- Practical Considerations for Use of Renin-Angiotensin-Aldosterone System Inhibitors in Cardiometabolic Disease (RAASi: ACE-I, ARB, ARNI, MRA)
- Protocol for Use of Renin-Angiotensin-Aldosterone System Inhibitors in Cardiometabolic Disease (RAASi: ACE-I, ARB, ARNI, MRA)
- Practical Considerations for Use of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)
- Protocol for Use of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)
- Prescribing Insulin and Diabetes Supplies: Quick Reference
- Risk Assessment Tools and Health Screening Instruments Commonly Used in Cardiometabolic Patients
Press Releases
- Amgen becomes a Supporting Sponsor of the Cardiometabolic Center Alliance
- Atlantic Health System joins the Cardiometabolic Center Alliance as a Charter Member, 1st in NJ
- Atrium Health Wake Forest Baptist Joins the Cardiometabolic Center Alliance as a Charter Member
- Baptist Health South Florida Joins the Cardiometabolic Center Alliance as a Charter Member
- Bryan Heart Joins the Cardiometabolic Center Alliance as a Charter Member
- CMCA Executive Director Presents Late Breaking Clinical Trial
- Essentia Health Joins the Cardiometabolic Center Alliance as a Charter Member
- Major Health Partners Joins the Cardiometabolic Center Alliance as a Charter Member
- Northwell Health Joins the Cardiometabolic Center Alliance as a Charter Member
- Our Lady of the Lake Heart & Vascular Institute Joins the Cardiometabolic Center Alliance as a Charter Member
- Saint Luke’s Mid America Heart Institute Announces Launch of National Cardiometabolic Center Alliance
- The Cardiometabolic Center Alliance Announces Boehringer Ingelheim as a Sponsor
- TriHealth Joins the Cardiometabolic Center Alliance as a Charter Member
- University Hospitals Cleveland Medical Center Joins as a Key Strategic Partner and Charter Member
- Video: Launch of Cardiometabolic Center Alliance